Literature DB >> 19523352

Convulsive and nonconvulsive status epilepticus in children.

Nicholas S Abend1, Eric Marsh.   

Abstract

Status epilepticus (SE) is a common pediatric neurologic emergency that requires rapid assessment and management. Treatment of pediatric SE involves two equally important factors. First, rapid identification of the underlying etiology is essential, as decisions on how to treat and prognosticate depend on the cause of SE. Second, the timing of treatment initiation with adequate doses is crucial, as early action is most effective in terminating SE and decreasing morbidity and mortality. Currently, early treatment with adequate doses of a benzodiazepine is appropriate, followed by treatment with phenytoin, phenobarbital, or valproic acid. If the seizure does not stop or repetitive seizures continue, the addition of other medications (eg, levetiracetam) or pharmacologic coma induction may be indicated. This review evaluates treatment protocols for acute SE, prolonged SE, and nonconvulsive SE, including some management strategies that use newer anticonvulsants.

Entities:  

Year:  2009        PMID: 19523352     DOI: 10.1007/s11940-009-0030-8

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  50 in total

1.  High-dose midazolam therapy for refractory status epilepticus in children.

Authors:  Gavin Morrison; Elizabeth Gibbons; William Patrick Whitehouse
Journal:  Intensive Care Med       Date:  2006-09-15       Impact factor: 17.440

2.  Very-high-dose phenobarbital for childhood refractory status epilepticus.

Authors:  Wai Kin Lee; Kam Tim Liu; Betty Wan Yin Young
Journal:  Pediatr Neurol       Date:  2006-01       Impact factor: 3.372

3.  Frequency and predictors of nonconvulsive seizures during continuous electroencephalographic monitoring in critically ill children.

Authors:  Nathalie Jette; Jan Claassen; Ronald G Emerson; Lawrence J Hirsch
Journal:  Arch Neurol       Date:  2006-12

4.  Intramuscular midazolam vs intravenous diazepam for acute seizures.

Authors:  Ira Shah; C T Deshmukh
Journal:  Indian J Pediatr       Date:  2005-08       Impact factor: 1.967

5.  Pediatric refractory partial status epilepticus responsive to topiramate.

Authors:  Lubov Blumkin; Tally Lerman-Sagie; Tzion Houri; Eli Gilad; Andrea Nissenkorn; Mira Ginsberg; Nathan Watemberg
Journal:  J Child Neurol       Date:  2005-03       Impact factor: 1.987

6.  Nonconvulsive status epilepticus in children: clinical and EEG characteristics.

Authors:  Stacey K H Tay; Lawrence J Hirsch; Linda Leary; Nathalie Jette; John Wittman; Cigdem I Akman
Journal:  Epilepsia       Date:  2006-09       Impact factor: 5.864

7.  Treatments with midazolam and lidocaine for status epilepticus in neonates.

Authors:  Hitoshi Yamamoto; Masao Aihara; Shinichi Niijima; Hideo Yamanouchi
Journal:  Brain Dev       Date:  2007-04-16       Impact factor: 1.961

Review 8.  Revising a dogma: ketamine for patients with neurological injury?

Authors:  Sabine Himmelseher; Marcel E Durieux
Journal:  Anesth Analg       Date:  2005-08       Impact factor: 5.108

9.  Intravenous lidocaine for status epilepticus during childhood.

Authors:  Shin-ichiro Hamano; Nobuyoshi Sugiyama; Shintaro Yamashita; Manabu Tanaka; Mika Hayakawa; Motoyuki Minamitani; Satoshi Yoshinari; Yoshikatsu Eto
Journal:  Dev Med Child Neurol       Date:  2006-03       Impact factor: 5.449

10.  Aborted and refractory status epilepticus in children: a comparative analysis.

Authors:  Florise A C P Lambrechtsen; Jeffrey R Buchhalter
Journal:  Epilepsia       Date:  2007-12-18       Impact factor: 5.864

View more
  2 in total

Review 1.  Continuous EEG monitoring in the intensive care unit.

Authors:  Jeffrey D Kennedy; Elizabeth E Gerard
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

2.  Management of convulsive status epilepticus in children: an adapted clinical practice guideline for pediatricians in Saudi Arabia.

Authors:  Fahad A Bashiri; Muddathir H Hamad; Yasser S Amer; Manal M Abouelkheir; Sarar Mohamed; Amal Y Kentab; Mustafa A Salih; Mohammad N Al Nasser; Ayman A Al-Eyadhy; Mohammed A Al Othman; Tahani Al-Ahmadi; Shaikh M Iqbal; Ali M Somily; Hayfaa A Wahabi; Khalid J Hundallah; Ali H Alwadei; Raidah S Albaradie; Waleed A Al-Twaijri; Mohammed M Jan; Faisal Al-Otaibi; Abdulrahman M Alnemri; Lubna A Al-Ansary
Journal:  Neurosciences (Riyadh)       Date:  2017-04       Impact factor: 0.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.